PET using 11C-methionine in recognition of pseudoprogression in cerebral glioma after combined treatment

Skvortsova T.Iu.; Brodskaia Z.L.; Gurchin A.F.

doi:https://doi.org/

Skvortsova T.Iu.

FGBUN "Institut mozga cheloveka im. N.P. Bekhterevoĭ" RAN, Sankt-Peterburg

Brodskaia Z.L.

FGBUN "Institut mozga cheloveka im. N.P. Bekhterevoĭ" RAN, Sankt-Peterburg

Gurchin A.F.

FGBUN "Institut mozga cheloveka im. N.P. Bekhterevoĭ" RAN, Sankt-Peterburg

PET using 11C-methionine in recognition of pseudoprogression in cerebral glioma after combined treatment

Authors:

Skvortsova T.Iu., Brodskaia Z.L., Gurchin A.F.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2014;78(4): 50‑58

Read: 2411 times

To cite this article:

Skvortsova TIu, Brodskaia ZL, Gurchin AF. PET using 11C-methionine in recognition of pseudoprogression in cerebral glioma after combined treatment. Burdenko's Journal of Neurosurgery. 2014;78(4):50‑58. (In Russ., In Engl.)

Подписка 2025 Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко (Burdenko's Journal of Neurosurgery)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Modern strategies for early diagnosis of cardiotoxicity caused by chemotherapy. Russian Journal of Preventive Medicine. 2025;(11):113-120

Abstract:

The purpose of the study was to evaluate the value of PET using 11C-methionine (PET-Met) for distinction between true glioma progression and pseudoprogression (PsPr). 72 patients with treated cerebral glioma investigated by PET-Met were identified from prospective database. Entry criteria included new or progressive MR imaging enhancing lesions within first 6 months after irradiation and definite final diagnosis on the basis of the pathological study (n=17) or clinical-radiological follow-up on an average 16 months. PET examinations were assessed by visual inspection and calculating 11C-methionine uptake index (UI). Results. Pseudoprogression was defined as early radiological progression with subsequent regress or stabilization, without salvage therapy. 42 patients were considered to exhibit PsPr and 30 patients had true glioma progression. In PsPr group PET scans were either negative (n=6) or slightly increased tracer uptake (UI range 1.2-2.14) was seen in the site of contrast-enhanced lesion. The UI was 1.48±0.39 (mean±SD). In comparison with pretreatment PET 15 patients showed decrease 11C-methionine uptake on an average by 26%. In recurrence group PET-Met showed abnormal high focal 11C-methionine uptake in the lesion. The UI was 2.54±0.84 (range 1.54-5.4). An UI threshold value of greater than 1.9 optimized differentiation between glioma progression and PsPr with sensitivity of 83.5% and specificity of 97.0%. Conclusion. Metabolic characteristics of PsPr included negative tracer accumulation or slightly increased 11C-methionine uptake in the contrast-enhancing lesion with UI less than 1.9.

Keywords:

PET

11C-methionine

pseudoprogression

recurrent glioma

Authors:

Skvortsova T.Iu.

FGBUN "Institut mozga cheloveka im. N.P. Bekhterevoĭ" RAN, Sankt-Peterburg

Brodskaia Z.L.

FGBUN "Institut mozga cheloveka im. N.P. Bekhterevoĭ" RAN, Sankt-Peterburg

Gurchin A.F.

FGBUN "Institut mozga cheloveka im. N.P. Bekhterevoĭ" RAN, Sankt-Peterburg

Close metadata

References:

Korsakov M.V., Krasikova R.N., Solov’ev D.V. The robotic synthesis of L-¹¹C-methyl-methionine. Radiokhimiya 1994; 37: 3: 272-274.In Russian.
Skvortsova T.Yu., Brodskaya Z.L., Gurchin A.F. et al. The diagnostic accuracy of PET with ¹¹C-methionine in delineation of continued growth of primary cerebral tumors and radiation-induced brain injuries. Med Vizualizatsiya 2011; 6: 80-92. In Russian.
Brandes A.A., Franceshi E., Tosoni A. et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26: 13: 2192-2197.
Brandes A.A., Tosoni A., Spagnolli F. et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro-Oncol 2008; 10: 361-367.
Brandsma D., van den Bent M.J. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 2009; 22: 6: 633-638.
Chakvarti A., Erkkinen M.G., Nestler U. et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006; 12: 4738-4746.
Chamberlain M.C.,Glantz M.J., Chalmers L. et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007; 82: 1: 81-83.
Chaskis C., Neyns B., Michotte A. et al. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol 2009; 72: 4: 423-428.
Clarke J.L., Chang S. Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci 2009; 9: 241-246.
de Wit M.C., de Bruin H.G., Eijkenboom W. et al. Immediate post-radiothera-py changes in malignant glioma can mimic tumor progression. Neurology 2004; 63: 3: 535-537.
Fink J., Born D., Marc C. et al. Pseudoprogression: relevance with respect to treatment of high-grade gliomas. Curr Treat Opt Oncol 2011; 12: 240-252.
Hoffman W.F., Levin V.A., Wilson C.B. Evaluation of malignant glioma patients during the postirradiation period. J Neurosurg 1979; 50: 5: 624-628.
Holdhoff M., Grossman S.A. Controversies in the adjuvant therapy of high-grade gliomas. Oncologist 2011; 16: 3: 351-358.
Hygino da Cruz Jr.L.C., Rodriguez I., Domingues R.C. et al. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatmant glioma. Am J Neurorad 2011; 32: 11: 1978-1985.
Kong D.S., Kim S.T., Kim E.H. et al. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. Am J Neuroradiol 2011; 32: 2: 382-387.
Meyzer C., Dhermain F., Ducreux D. et al. A case report of pseudoprogression followed by complete remission after proton-bean irradiation for a low-grade glioma in a teenager: the value of dynamic contrast-enhanced MRI. Radiat Oncol 2010; 4: 5-9.
Miyatake S., Kawabata S., Nonoguchi N. et al. Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas. Neuro Oncol 2009; 11: 4: 430-436.
Peca C., Pacelli R., Elefante A. et al. Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? Clin Neurol Neurosurg 2009; 111: 4: 331-334.
Perry A., Schmidt R.E. Cancer-therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol 2006; 111: 3: 197-212.
Roldán G.B., Scott J.N., Mclntyre J.B. et al. Population-based study of pseudoprogression after chemoradiotherapy in GBM. Can J Neurol Sci 2009; 36: 5: 617-622.
Taal W., Brandsma D., de Bruin H.G. et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008; 113: 2: 405-410.
Topkan E., Topuk S., Oymak E. et al. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. Am J Clin Oncol 2012; 35: 3: 284-289.
Yaman E., Buyukberber S., Benekli M. et al. Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. Clin Neurol Neurosurg 2010; 112: 8: 662-667.